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Abstract
Background: Recent GWAS and subsequent confirmation studies reported several single-nucleotide polymorphisms (SNPs)
at the CLU, CR1 and PICALM loci in association with late-onset Alzheimer’s disease (AD). Parkinson disease (PD) shares several
clinical and pathologic characteristics with AD; we therefore explored whether these SNPs were also associated with PD risk.
Methodology/Principal Findings: 791 non-Hispanic Whites cases and 1,580 matched controls were included in the study.
Odds ratios (OR) and 95% confidence intervals (CI) were obtained from logistic regression models. rs11136000 at the CLU
locus was associated with PD risk under the recessive model (comparing TT versus CC+CT: OR=0.71, 95% CI: 0.55-0.92,
p=0.008) after adjusting for year of birth, gender, smoking, and caffeine intake. Further adjustment for family history of PD
and ApoE e4 status did not change the result. In addition, we did not find evidence for effect modification by ApoE or
known PD risk factors. The association, however, appeared to be stronger for PD with dementia (OR=0.49, 95% CI: 0.27-
0.91) than for PD without dementia (OR=0.81, 95% CI: 0.61-1.06). The two other SNPs, rs6656401 from CR1, and rs3851179
from PICALM region were not associated with PD (p.0.05).
Conclusion: Our exploratory analysis suggests an association of CLU with PD. This exploratory finding and the role of
dementia in explaining this finding needs further investigation.
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Introduction
Alzheimer’s disease (AD) and Parkinson disease (PD) are the two
most common neurodegenerative diseases among the elderly.
These two conditions share several clinical and pathological
characteristics. For example, they both are clinically progressive
and involve abnormal protein depositions [1]. Further, more than
half of PD patients eventually develop dementia [2], and
conversely, parkinsonian signs are common among Alzheimer
patients [3]. Finally, although not entirely consistent [4],
preliminary data suggest that individuals with a family history of
PD may have a higher risk for AD [5,6,7,8]. These links suggest
that AD and PD may have some shared risk factors and/or
common pathogenic mechanisms. However, to date, little effort
has been made to search for potential genetic or environmental
risk factors that may contribute to both diseases.
Recent large genome-wide association studies (GWAS) have
reported several novel susceptibility genetic loci for late onset AD,
including clusterin (CLU) [9,10], complement component (3b/4b)
receptor 1 (CR1) [10] and the phosphatidylinositol binding clathrin
assembly protein (PICALM) [9]. These findings were subsequently
confirmed in a large pooled sample of AD cases and controls [11].
We therefore explored the relationship of PD with selected SNPs
from the AD GWAS studies (rs11136000 for CLU, rs6656401 for
CR1, and for rs3851179 for PICALM) in a large PD case-control
study.
Results
Table 1 shows population characteristics according to case-
control status. As expected, Parkinson patients were less likely to
be smokers and drank less caffeinated drinks than controls
(p,0.0001). Compared with controls, they were also less likely
to be ApoE e4 carriers, but more likely to report a family history of
PD. Among Parkinson cases, the average age at onset was
65.767.4 years and the average age at diagnosis was 66.667.4
years. Approximately 19% of Parkinson patients had dementia as
reported by their treating physician or by medical record review,
and the prevalence of dementia was higher among Parkinson
patients diagnosed before 2000 (23.6%) than those diagnosed after
2000 (13.9%).
All SNPs in controls conformed to Hardy-Weinberg equilibrium
(p.0.05). None of the SNPs examined was related to PD risk
under the additive models or dominant models; however,
rs11136000 at the CLU locus was associated with PD risk under
the recessive model (Table 2). After adjusting for year of birth,
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mately 29% lower odds of having PD compared to participants
with other genotypes (OR=0.71, 95%CI: 0.55-0.92). Further
adjustment for family history and ApoE e4 status did not change
the result (OR=0.74, 95%CI: 0.57-0.95). Subgroup analyses
generally showed similar results (Figure 1). The results were also
similar for cases diagnosed before 2000 (OR=0.76, 95%CI: 0.55-
1.07) and for cases diagnosed after 2000 (OR=0.69, 95%CI: 0.50-
0.95). When PD cases with and without dementia were analyzed
separately, the association appeared to be stronger for PD with
dementia (recessive model OR=0.49, 95%CI: 0.27-0.91) than for
PD without dementia (OR=0.81, 95%CI: 0.61-1.06); however,
the associations were in the same direction and 95% CIs
overlapped. In contrast to CLU, SNPs at the PICALM and CR1
loci were not associated with PD risk in all analyses.
Discussion
In this large case-control analysis, we found preliminary
evidence that rs11136000 at the CLU locus might be associated
with PD, and this association appeared to be stronger for PD
patients with dementia. Our analyses also suggest that this
relationship was independent of ApoE or known risk factors for PD.
Several clinical and pathological similarities between PD and
AD have led to the hypothesis that these two conditions may share
some pathogenic mechanisms or risk factors [1,12]. ApoE e4, the
most established genetic risk factor for AD, has been examined in
relation to PD in over 30 case-control studies. Most prior studies
reported a null association between ApoE e4 and PD [13,14],
although a few reported either higher or lower PD prevalence
among e4 carriers [15,16,17,18]. We also examined ApoE e4 in our
study sample. We found that while ApoE e4-carriers had a higher
prevalence of dementia than non-carriers among PD patients,
ApoE e4 was associated with a statistically significant lower risk of
PD (OR: 0.75, 95%CI: 0.59-0.94) [19]. Although this result needs
confirmation from other studies, it is consistent with several
previous epidemiological observations that higher plasma choles-
terol was associated with a lower risk for PD [20,21,22].
Two recent large GWAS [9,10] have independently indentified
rs11136000 at the CLU locus as a risk allele for late onset AD, and
the finding was subsequently confirmed in a large case-control study
and a meta-analysis [11]. Clusterin may have diverse biological
functions; however, the exact mechanisms how clusterin affects AD
pathogenesis are yet to be unveiled [23]. Several hypotheses have
been proposed, including actions on amyloid-b deposition or
clearance, cell survival, neuroinflammation, or lipid trafficking
[23,24]. Some of these biological processes have also been
implicated in PD pathogenesis. Direct explorations of potential
roles of clusterin in Parkinson pathogenesis are rare. Preliminary
evidence suggests that clusterin may affect the formation of Lewy
body by acting as a chaperone [25,26]. Further, a recent clinical
study found that PD patients had significantly higher levels of
clusterin in the cerebrospinal fluid than in controls [27].
An alternative explanation is that the finding was mediated by
an association of CLU with PD dementia. In support of this, we
found that the association was stronger for PD dementia than for
PD without dementia, although both associations were in the same
direction. The presence of dementia in our study was collected
only as part of PD diagnostic confirmation and thus we were
unable to examine this possibility in details. Therefore, if our
finding is confirmed, future studies should also investigate the
possibility that the association of CLU with PD might be explained
by its potential association with dementia.
CR1 [10] and PICALM [9] were each implicated in one of the
above referenced AD GWAS. CR1 encodes complement receptor
1, and may play a role in neuroinflammation and amyloid
clearance [24]. On the other hand, PICALM encodes a
ubiquitously expressed phosphatidylinositol-binding clathrin as-
sembly protein which may affect synaptic neurotransmission and
trafficking [24]. In our study sample, SNPs selected for these two
genetic loci were not associated with PD risk. The later meta-
analysis of AD GWAS data [11] found that rs3821179 at the
PICALM locus was only associated with AD risk among ApoE e4
Table 1. Population characteristics of Parkinson Cases and
controls.
Case (%) Control (%) P
#
All 791 1580
Men 604 (76.4) 1244 (78.7)
Women 187 (23.6) 336 (21.3) 0.19
Year of Birth
1925-1929 283 (35.8) 616 (39.0)
1930-1934 264 (33.4) 558 (35.3)
1935-1939 160 (20.2) 264 (16.7)
1940- 84 (10.6) 142 (9.0) 0.07
Smoking status ,.0001
Never 368 (46.5) 555 (35.1)
Former 388 (49.1) 916 (58.0)
Current 24 (3.0) 93 (5.9)
Missing 11 (1.4) 16 (1.0)
Caffeine intake (mg/day) 296.56338.0 359.86359.9 ,.0001
Family History of PD ,.0001
Yes 112 (14.2) 86 (5.4)
No 672 (85.0) 1356 (85.2)
Missing 7 (0.9) 138 (8.7)
Age at diagnosis (n=781*) 66.667.4 NA
Age at first symptoms (n=642*) 65.767.4 NA
Year of diagnosis
Before 2000 363 NA
2000 and after 428 NA
CLU: rs11136000
CC 281 (35.8) 569 (36.1)
CT 402 (51.2) 746 (47.3)
TT 102 (13.0) 261 (16.6) 0.05
PICALM: rs3851179
GG 298 (38.5) 631 (40.4)
GA 359 (46.3) 716 (45.8)
AA 118 (15.2) 215 (13.8) 0.52
CR1: rs6656401
GG 522 (66.8) 1028 (65.5)
GA 233 (29.8) 493 (31.4)
AA 27 (3.5) 48 (3.1) 0.66
ApoE: e4
e4 carrier 631 (80.0) 1166 (75.6) 0.02
Non-e4 carrier 158 (20.0) 376 (24.4)
#Chi-Square tests for categorical variables, t-tests for continuous variables
*number of participants that provided data.
doi:10.1371/journal.pone.0024211.t001
CLU and Parkinson
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between rs3821179, or any other SNPs, and ApoE e4 allele [6].
Unlike clusterin, for which there is preliminary experimental
evidence, we are not aware of any evidence suggesting a link
between CR1 or PICALM and PD.
To the best of our knowledge, this is the first attempt to examine
recent AD GWAS findings in PD pathogenesis. Therefore, our
analyses should be considered exploratory and hypothesis generat-
ing; accordingly, we explored the associations under different
genetic models and did not adjust for multiple comparisons.
Although this study is among the larger population based genetic
studies on PD, the statistical power was limited. For example, we
had only an adequate statistical power for a common SNP (minor
allelefrequency$38.5%)andamoderateassociation(OR#0.69or
$1.38) under a recessive model. For this consideration, we only
chose the most significant SNPs in previous AD GWAS. Further, it
is important to point out that the previous AD GWASanalyses were
based on additive model, but our analysis on rs11136000 was only
statistically significant under recessive model. Due to these
uncertainties, our finding on rs11136000 only suggests a potential
link to this genomic locus; future studies with larger sample size and
denser SNP coverage are needed to confirm our result, and if
confirmed, further investigations would be needed to identify the
underlying gene and functional SNPs.
In this study, we confirmed the diagnosis of PD with patients’
treating physicians, rather than having the diagnosis uniformly
made by study related movement disorder specialists. We therefore
could not exclude the possibility of a few misdiagnoses.
Nevertheless, recent clinicopathological studies showed a 90%
accuracy for PD diagnosis made by clinical neurologists [28]. We
were also concerned about the possibility that cohort participants
with dementia might have been less likely to participate in this
study than participants without dementia. This factor, however,
might have similarly affected both cases and controls. Further,
results from sensitivity analyses stratified by the year of PD
diagnosis or baseline age showed similar results across subgroups.
We therefore expect the impact from this bias is likely to be
limited. With the same reasoning, we expect that poor health or
poor survival of prevalent PD patients might also have limited
impacts on the analysis. Finally, the current analysis was
conducted among non-Hispanic Whites, therefore the generaliz-
ability of these findings to other ethnicities is uncertain.
Methods
Patients
PD cases and controls were from the Parkinson’s, Genes, and
Environment (PAGE) study that was nested within the large
Table 2. Parkinson’s disease in relation to SNPs associated with AD.
Models CLU - rs11136000 *b/B=T/C PICALM - rs3851179 *b/B=A/G CR1 - rs6656401 *b/B=A/G
Case/Control 785/1576
# 775/1562
# 782/1569
#
OR (95%) CI p OR (95%) CI p OR (95%) CI p
Additive Model01 0.92(0.8101.04) 0.17 1.07(0.9401.21) 0.32 0.99(0.8401.16) 0.86
Model 2 0.91(0.80 1.04) 0.18 1.08(0.95 1.23) 0.25 0.99(0.84 1.16) 0.88
Dominant/ (Bb+bb) vs BB Model 1 1.00(0.84 1.20) 0.96 1.07(0.89 1.28) 0.48 0.96(0.80 1.16) 0.68
Model 2 0.98(0.82 1.18) 0.86 1.10(0.91 1.32) 0.33 0.95(0.79 1.15) 0.60
Recessive/ bb vs (BB+Bb) Model 1 0.71(0.55 0.92) 0.008 1.13(0.88 1.45) 0.34 1.15(0.71 1.87) 0.57
Model 2 0.74(0.57 0.95) 0.02 1.13(0.88 1.45) 0.36 1.27(0.77 2.09) 0.35
*b: minor allele; B: major allele;
# numbers of participants to be genotyped successfully.
Model 1: logistic models adjusted for year of birth, gender, smoking status, and daily caffeine intake.
Model 2: further adjusted for family history of PD and ApoE e4 status (e4 carrier and Non-e4 carrier).
doi:10.1371/journal.pone.0024211.t002
Figure 1. Stratified analysis of the relationship between
rs11136000 and PD based on the recessive model (TT vs TC/
CC), adjusted for year of birth, gender, smoking status, and
daily caffeine intake. None of the interactions were statistically
significant.
doi:10.1371/journal.pone.0024211.g001
CLU and Parkinson
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Diet and Health Study cohort (Formerly known as American
Association of Retired Persons. [29]. This cohort was established in
1995-1996 for research on cancer and other chronic diseases and
collected detailed dietary and lifestyle data at baseline [29].
Potential PD patients in this cohort were identified from self-reports
in the cohort’s follow-up survey in 2004-2006, which asked
participants whether they had ever been informed by a doctor that
they had PD. We then contacted surviving self-reported cases to
verify the diagnosis and to collect saliva samples for genetic analysis.
Detailed procedures for case confirmation were published previ-
ously [30]. Briefly, we first obtained confirmation and permission
from self-reported PD patients and then contacted their treating
physicians to complete diagnostic form and a copy of the relevant
medical record. As part of this clinical data collection, we also
collected information on the dates of first symptoms and diagnosis,
the presence of dementia, and the family history of PD among first
degree biological relatives. The Parkinson case was confirmed if the
diagnosis was either validated by the patient’s treating physician or
by medical record review showing a final PD diagnosis or at least
two cardinal signs of PD with one being resting tremor or
bradykinesia, a progressive course, and the absence of unrespon-
siveness to levodopa or other features suggesting an alternative
diagnosis. Only physician confirmed PD cases (86.7% by neurol-
ogist and movement disorder specialists) were included in the
analysis. A similar procedure was successfully used in other large
cohorts [31,32,33]. Potential controls were randomly selected from
cohort participants who did not report PD in the follow-up survey,
frequency matched to self-reported cases on year of birth, gender,
and ethnicity. Saliva samples were obtained from cases and controls
using Oragene
TM saliva collection kits (DNA Genotek Inc., Ontario
Canada). For controls, family history of PD was asked as part of the
saliva collection. A total of 838 physician confirmed PD cases and
1,703 controls were genotyped for the current analyses. To avoid
population stratification, we excluded 30 cases and 80 controls who
were not non-Hispanic Whites or had missing information on
ethnicity. We further excluded 17 cases and 43 controls who failed
genotyping on all three SNPs, leaving us a total of 791 cases and 1,
580 controls for the final analyses. The study protocol was approved
by the Institutional Review Board of the National Institute of
Environmental Health Sciences with written consent from all study
participants.
Exposure Assessment
The baseline questionnaire of the NIH-AARP Diet and Health
Study collected detailed data on diet, lifestyle, and population
demographics, including birth date, gender, and ethnicity (Non-
Hispanic White, Non-Hispanic Black, Hispanic, Asian, Pacific
Islander, or American Indian/Alaskan Native) [29]. In addition,
we asked participants to report whether they had ever smoked
more than 100 cigarettes during their lifetime; and for ‘‘ever
smokers’’, we further asked for the typical amount of smoking,
current smoking status and years since last smoking. Daily caffeine
intake was derived from the baseline dietary survey.
DNA extraction and genotyping
DNA was extracted from saliva samples collected with the
Oragene
TM collection kits. Three SNPs were selected based on
their statistical significance as reported in the GWAS, one for each
gene region: rs11136000 for CLU, rs6656401 for CR1, and
rs3851179 for PICALM. One additional SNP on PICALM was
also selected based on information from ALZgene.com; this SNP is
in linkage disequilibrium with rs3851179 and the results were also
similar, so we did not present detailed data for that particular SNP.
Genotyping was performed by BioServe Biotechnologies, Ltd.,
Beltsville, MD, using MassARRAY iPLEXTM platform (Seque-
nom, San Diego CA). Sequenom is a PCR and mass spectrometry
based system. Genotyping assays are custom developed using Mass
ARRAY Assay Design 3.1 software. For quality control purpose,
we randomly included 51 duplicated saliva DNA samples which
were kept blinded to the genotyping laboratory; the genotyping
reproducibility was 100%.
Statistical analyses
We examined Hardy-Weinberg equilibrium with chi-square
statistics. Odds ratios (ORs) and 95% confidence intervals (CIs)
were derived from logistic regression models, adjusting for year of
birth (in four groups), gender, smoking status (never, former,
current) and daily caffeine intake (quintile). We also further
adjusted for family history of PD and ApoE e4 status. We
examined each individual allele in relation to PD first under an
additive model and then under dominant and recessive models.
We began the analyses with all participants, and then stratified by
individual covariates: year of birth (below or above median),
gender (men vs. women), smoking status (never vs. ever smokers)
caffeine intake (below or above median), family history of PD (Yes
vs. No), and ApoE e4 status (e4 carriers vs. non- e4 carriers).
To examine the potential influence of bias stemming from the
possibility that PD cases with dementia were less likely to
participate in the study than PD cases without dementia, we
conducted a sensitivity analysis to examine the association of genes
with PD separately for cases diagnosed before the year 2000 and
diagnosed after the year 2000. We assumed that cases with longer
duration of PD (e.g. diagnosed before 2000) were more likely to
have dementia than cases with shorter duration, and therefore
such a bias would affect the analyses for cases with years of PD
more so than for recent cases. With the same reasoning, stratified
analysis by age may also help clarify the potential influence of
dementia as the prevalence of dementia increases dramatically
with age. Finally, we also analyzed rs11136000 at the CLU locus
separately in relation to PD with dementia and PD without
dementia. Statistical analyses were performed using SAS version
9.2 (SAS Institute Inc, Cary, NC) combined with Plink v1.07. Post-
hoc power calculation was performed with Quanto V1.2.4 [34].
Two sided p,0.05 was considered statistically significant.
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